What Is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer?

  • Alok Pant
  • Nobuyuki Susumu
  • Takafumi Toita
  • Satoru Sagae
  • William SmallJr.


Cervical cancer is a significant contributor to worldwide morbidity and mortality. Combined chemotherapy and radiation has recently become widely prevalent in the treatment of locally advanced disease. The use of adjuvant chemotherapy following surgery for early-stage disease remains experimental, and the appropriate regimen is not yet clearly defined. Combined chemoradiation following by adjuvant chemotherapy has shown potential benefit in appropriately selected patients, though an increase in toxicity rates has been noted. Neoadjuvant chemotherapy before a surgery is controversial with prior reports showing differing results and continued ongoing trials. Similar to adjuvant chemotherapy, the appropriate regimen remains undefined. Chemotherapy for widely metastatic or for recurrent disease, while still palliative in nature, is undergoing a transformation from regimens with significant toxicity and minimal survival benefit to those regimens with improved side effect profile and steady gains in clinical activity. Numerous international trials are under way trying to improve outcomes in this unfortunate patient population. Targeted therapy for cervical cancer remains in its infancy, but research continues in the laboratory and clinical setting aiming to improve outcomes. International collaboration via cooperative group trials remains the cornerstone for the advancement of care for patients with cervical cancer.


Overall Survival Cervical Cancer Radiation Therapy Oncology Group Radical Hysterectomy Gynecologic Oncology Group 


  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality, and prevalence worldwide. Version 1.1, IARC Cancer Base No. 5. Lyon: IARC Press; 2001.Google Scholar
  3. 3.
    Kolstad P. Follow-up study of 232 patients with stage IA1 and 411 patients with stage IA2 squamous cell carcinoma of the cervix (microinvasive carcinoma). Gynecol Oncol. 1989;33:265–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe EW, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–61.PubMedCrossRefGoogle Scholar
  5. 5.
    Yamamoto K, Izumi R, Hasegawa K. Adjuvant oral 5-fluorouracil for cervical cancer: Japanese gynecologic oncology group report. Int J Oncol. 2004;24:1175–9.PubMedGoogle Scholar
  6. 6.
    Lorvidhaya V, Chitapanarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys. 2003;55:1226–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Hosaka M, Watari H, Kato T, et al. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy. J Surg Oncol. 2012;105:612–6. doi: 10.1002/jso.22136.PubMedCrossRefGoogle Scholar
  8. 8.
    Takeshima N, Umayahara K, Fujiwara K, et al. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Gynecol Oncol. 2006;103:618–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Matsumura M, Takeshima N, Ota T, et al. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for stage IB2-IIB cervical cancer – irinotecan and platinum chemotherapy. Gynecol Oncol. 2010;119:212–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Tierney J, Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39:2470–86.CrossRefGoogle Scholar
  11. 11.
    Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002;20:179–88.PubMedCrossRefGoogle Scholar
  12. 12.
    Chang TC, Lai CH, Hong JH, Hsueh S, Huang KG, Chou HH, Tseng CJ, Tsai CS, Chang JT, Lin CT, Chang HH, Chao PJ, Ng KK, Tang SG, Soong YK. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol. 2000;18:1740–7.PubMedGoogle Scholar
  13. 13.
    Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, Snaidas L, Vighi S, Gomez Rueda N, di Paola G. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol. 1997;67:61–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Napolitano U, Imperato F, Mossa B, Framarino ML, Marziani R, Marzetti L. The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial. Eur J Gynaecol Oncol. 2003;24:51–9.PubMedGoogle Scholar
  15. 15.
    Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O’Connor D. Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007;106:362–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol. 2008;110:308–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Cai HB, Chen HZ, Yin HH. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res. 2006;32:315–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A, Mohar A, Rivera L, Mota A, Guadarrama R, Chanona G, De La Garza J. Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. Ann Oncol. 2002;13:1212–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ryu HS, Kang SB, Kim KT, Chang KH, Kim JW, Kim JH. Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer. 2007;17:132–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96:805–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Yin M, Zhang H, Li H, Li X, Liu Y, Chen X, Lou G, Li K. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol. 2012;105:206–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Peters 3rd WA, Liu PY, Barrett RJ, Gordon Jr W, Stock R, Berek JS, et al. Cisplatin and 5-FU plus radiation therapy are superior to radiation therapy as adjunctive in high- risk early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study. J Clin Oncol. 2000;18: 1606–13.PubMedGoogle Scholar
  23. 23.
    Monk BJ, Wang J, Im S, Stock RJ, Peters III WA, Liu PY, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005;96:721–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Thomas GM, Dembo AJ. Is there a role for adjuvant pelvic radiotherapy after radical hysterectomy in early stage cervical cancer? Int J Gynecol Cancer. 1991;1:1–8.CrossRefGoogle Scholar
  25. 25.
    Sedlis A, Bundy BN, Rotman M, Lentz S, Muderspach LI, Zaino R. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;73:177–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76.PubMedCrossRefGoogle Scholar
  27. 27.
    Pieterse QD, Trimbos JBMZ, Dijkman A, Creutzberg CL, Gaarenstroom KN, Peters AAW, Kenter GG, et al. Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study. Int J Gynecol Cancer. 2006;16:1112–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Rose PG, Bundy B, Watkins EB, Thigpen T, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, et al. Long term follow-up of a randomized trial comparing concurrent single agent cisplatin or cisplatin-based combination chemotherapy for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:1–7.CrossRefGoogle Scholar
  30. 30.
    Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol. 2004;22:872–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, et al. Randomized comparison of fluorouracil plus cisplatin vs hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–48.PubMedGoogle Scholar
  33. 33.
    Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20(4):966.PubMedCrossRefGoogle Scholar
  34. 34.
    Tseng CJ, Chang CT, Lai CH, Soong YK, Hong JH, Tang SG, Hsueh S. A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix. Gynecol Oncol. 1997;66(1):52.PubMedCrossRefGoogle Scholar
  35. 35.
    Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;(1):CD008285.Google Scholar
  36. 36.
    Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802–12.PubMedCentralCrossRefGoogle Scholar
  37. 37.
    Umayahara K, Takeshima N, Nose T, Fujiwara K, Sugiyama Y, Utsugi K, Yamashita T, Takizawa K. Phase I study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel chemotherapy for locally advanced cervical carcinoma in Japanese women. Int J Gynecol Cancer. 2009;19(4):723–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Ryu SY, Lee WM, Kim K, Park S, Kim BJ, Kim MH, Choi SC, Cho CK, Nam BH, Lee ED. Randomized clinical trial of weekly vs tri-weekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e577–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29(13):1678–85.PubMedCrossRefGoogle Scholar
  40. 40.
    Mabuchi S, Ugaki H, Isohashi F, Yoshioka Y, Temma K, Yada-Hashimoto N, Takeda T, Yamamoto T, Yoshino K, Nakajima R, Kuragaki C, Morishige K, Enomoto T, Inoue T, Kimura T. Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone. Gynecol Obstet Invest. 2010;69:224–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Grigsby PW, Lu JD, Mutch DG, Kim RY, Eifel PJ. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92–10. Int J Radiat Oncol Biol Phys. 1998;41(4):817.PubMedCrossRefGoogle Scholar
  42. 42.
    Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Long-term follow-up of RTOG 92–10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001;51(4):982.PubMedCrossRefGoogle Scholar
  43. 43.
    Small Jr W, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68(4):1081.PubMedCrossRefGoogle Scholar
  44. 44.
    Small Jr W, Winter K, Levenback C, Iyer R, Hymes SR, Jhingran A, Gaffney D, Erikson B, Greven K. Extended field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of Arm II of RTOG 0116. Int J Gynecol Cancer. 2011;21(7):1266–75.PubMedGoogle Scholar
  45. 45.
    Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, Connelly P. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998;42(5):1015.PubMedCrossRefGoogle Scholar
  46. 46.
    Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J. 2003;9:425–32.PubMedCrossRefGoogle Scholar
  47. 47.
    Long III HJ. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25:2966–74.PubMedCrossRefGoogle Scholar
  48. 48.
    Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15(1):165.PubMedGoogle Scholar
  49. 49.
    Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113.PubMedCrossRefGoogle Scholar
  50. 50.
    Long 3rd HJ, Bundy BN, Grendys Jr EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(21):4626.PubMedCrossRefGoogle Scholar
  51. 51.
    Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of 4 Cisplatin containing doublet combinations in stage IVb, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27:1069–74.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Schefter TE, Winter K, Kwon JS, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012;83:1179–84.PubMedCrossRefGoogle Scholar
  54. 54.
    Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Alok Pant
    • 1
  • Nobuyuki Susumu
    • 2
  • Takafumi Toita
    • 3
  • Satoru Sagae
    • 4
  • William SmallJr.
    • 5
  1. 1.Department of Obstetrics and GynecologyNorthwestern Memorial HospitalChicagoUSA
  2. 2.Department of Obstetrics and GynecologySchool of Medicine, Keio UniversityShinjyuku-kuJapan
  3. 3.Department of RadiologyRyukyu University HospitalNishiharaJapan
  4. 4.Department of Obstetrics and GynecologyJR Sapporo HospitalSapporo, HokkaidoJapan
  5. 5.Chairman of Radiation OncologyLoyola University Medical CenterChicagoUSA

Personalised recommendations